All In Biotech

Drug Trial Radar · NCT06807463

A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

50

Actual

Start

Mar 31, 2025

Primary completion

Oct 2, 2026

Study completion Sep 14, 2027

Sponsor

Sponsor type
Industry
First posted
Feb 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary efficacy objective of the trial is to assess the ability of TEV-53408 to attenuate gluten-induced enteropathy in adults with celiac disease. The primary safety objective of the trial is to assess the safety of TEV-53408 in adults with celiac disease. A secondary objective is to further assess the efficacy of TEV-53408 in adults with celiac disease. The expected trial duration per participant is approximately 86 weeks.

Conditions

  • Celiac Disease

Interventions

  • TEV-53408Drug

    Solution for subcutaneous (sc) injection

  • PlaceboDrug

    Solution for subcutaneous (sc) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Villous Atrophy as Measured by Villous Height to Crypt Depth Ratio (Vh:Cd)Time frame: Baseline, Week 8
  2. Number of Participants With at Least One Treatment-Emergent Adverse EventTime frame: Up to Week 28
  3. Number of Participants With at Least One Treatment-Emergent Serious Adverse EventTime frame: Up to Week 28
  4. Number of Participants With at Least One Protocol-Defined Adverse Event of Special Interest (PDAESI)Time frame: Up to Week 28
  5. Number of Participants Who Discontinued From the Study Due to an Adverse EventTime frame: Up to Week 28

Locations

21 sites in 3 countries. Site status is shown where the registry gives one.

  • Teva Investigational Site 12138

    Murrieta, California

  • Teva Investigational Site 12131

    Colorado Springs, Colorado

  • Teva Investigational Site 12134

    Inverness, Florida

  • Teva Investigational Site 12126

    Miami Lakes, Florida

  • Teva Investigational Site 12135

    New Port Richey, Florida

  • Teva Investigational Site 12130

    Atlanta, Georgia

  • Teva Investigational Site 12133

    Marrero, Louisiana

  • Teva Investigational Site 12132

    Clinton Township, Michigan

  • Teva Investigational Site 12121

    Wyoming, Michigan

  • Teva Investigational Site 12129

    Rochester, Minnesota

  • Teva Investigational Site 12128

    New York, New York

  • Teva Investigational Site 12125

    Greenville, North Carolina

  • Teva Investigational Site 12127

    Winston-Salem, North Carolina

  • Teva Investigational Site 12137

    Waco, Texas

  • Teva Investigational Site 12122

    Ogden, Utah

  • Teva Investigational Site 12123

    Lynchburg, Virginia

  • Teva Investigational Site 78139

    Fitzroy, Australia

  • Teva Investigational Site 78140

    Maroochydore, Australia

  • Teva Investigational Site 78137

    Midland, Australia

  • Teva Investigational Site 40063

    Helsinki, Finland

  • Teva Investigational Site 40062

    Tampere, Finland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.